	US 12,253,515 B2
	Method for inhibiting the expression of cancer-promoting factors
Hiroshi Asahara, Tokyo (JP); Tomoki Chiba, Tokyo (JP); and Kentaro Abe, Osaka (JP)
Assigned to National University Corporation Tokyo Medical and Dental University, Tokyo (JP); and Nippon Zoki Pharmaceutical Co., Ltd., Osaka (JP)
Appl. No. 16/762,227
Filed by National University Corporation Tokyo Medical and Dental University, Tokyo (JP); and Nippon Zoki Pharmaceutical Co., Ltd., Osaka (JP)
PCT Filed Nov. 9, 2018, PCT No. PCT/JP2018/041758 § 371(c)(1), (2) Date May 7, 2020, PCT Pub. No. WO2019/093502, PCT Pub. Date May 16, 2019.
Claims priority of application No. 2017-216747 (JP), filed on Nov. 9, 2017.
Prior Publication US 2020/0355672 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/10 (2006.01); C12N 15/113 (2010.01); C12N 15/63 (2006.01); G01N 33/50 (2006.01)

CPC G01N 33/5011 (2013.01) [C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12Y 113/12007 (2013.01); G01N 2500/10 (2013.01)]

4 Claims

1. A method for inhibiting the expression of at least one cancer promoting factor comprising administering at least one RNA-binding motif, single-stranded-interacting protein 2 (RBMS2) expression inhibitor to a patient having at least one type of cancer in need of inhibition of the expression of at least one cancer promoting factor, wherein the at least one RBMS2 expression inhibitor is selected from the group consisting of a RBMS2-specific siRNA, a miRNA inhibiting the translation of a gene encoding RBMS2, a RBMS2-specific antisense nucleic acid, and expression vectors thereof.